Overview of Ultra-Levure

Property	Description
Active Ingredient	Saccharomyces boulardii (specific yeast strain)
Form	Capsules and powder for oral suspension
Pharmacological Class	Probiotic, Antidiarrheal micro-organism
General Purpose	Support for intestinal microbiota balance
Origin	Biological (non-pathogenic yeast)

What Type of Medicine is Ultra-Levure?

Ultra-Levure is a therapeutic agent classified as a probiotic and an antidiarrheal micro-organism used for gastrointestinal support. The product’s identity is defined by its active component, a unique non-pathogenic yeast belonging to the fungal kingdom, not a bacterium. This classification is clinically recognized as a key differentiator because the yeast structure provides inherent resistance to antibacterial medications. This unique trait allows the agent to function effectively during concurrent antibiotic therapy, offering critical support when the gut flora is disrupted.

Composition, Active Ingredient, and Forms

The active ingredient is the live micro-organism known as Saccharomyces boulardii, specifically the Saccharomyces cerevisiae HANSEN CBS 5926 strain. This single-ingredient product is delivered via the oral route of administration and is positioned for a wide target age range. The product is primarily available in two dosage forms: hard capsules and a powder for oral suspension contained in sachets, offering ease of use for both adults and pediatric patients. Ultra-Levure is a well-established brand in several European markets, providing a standard formulation that focuses specifically on delivering this robust yeast strain.

General Purpose and Action in the Gut

The general purpose of Ultra-Levure is to provide support for restoration of the intestinal microbiota and promote a healthy gut barrier function during times of instability. The primary action involves direct microbiota modulation as the introduced yeast helps re-establish a stable, balanced microbial environment. This specific strain helps restore the ecological balance in the gut. Furthermore, Saccharomyces boulardii provides trophic effects that support the intestinal lining and can bind certain harmful bacterial toxins, aiding in the stabilization of the digestive system following acute disturbances.

What side effects are possible with Ultra-Levure?

Adverse reactions associated with the use of Ultra-Levure (Saccharomyces boulardii) are classified according to the MedDRA System Organ Class (SOC) and standardized frequency categories as documented in official regulatory labeling.

Frequency-Classified Adverse Reactions

The most frequently cited effects are related to Gastrointestinal disorders. Flatulence is officially classified as a common adverse reaction. Constipation has also been reported in clinical use.

Adverse reactions affecting the Skin and subcutaneous tissue disorders and the Immune system disorders are listed, generally appearing with an uncommon frequency. These include localized allergic reactions such as pruritus (itching), urticaria (hives), a visible skin rash, and angioedema (swelling).

More severe systemic reactions, specifically anaphylactic reaction or shock, are documented, classified as rare serious adverse reactions.

Safety Considerations in At-Risk Populations

Due to the biological nature of the active ingredient, critical safety considerations exist for specific patient groups. The administration of Saccharomyces boulardii has been associated with the very serious adverse reaction of fungemia (presence of yeast in the blood culture) and sepsis in clinical reports. These events are reported predominantly in specific at-risk populations.

The risk of systemic infection is substantially increased in critically ill patients and immunocompromised patients (e.g., those with organ transplants or receiving chemotherapy). Individuals with a central venous catheter are explicitly cited in official regulatory documents as being particularly vulnerable to developing fungemia.

Safety Restrictions

Ultra-Levure must not be administered concurrently with systemic or oral antifungal drugs, as this may lead to a decrease in its therapeutic activity.

Overdose and Emergency Response

Overdose and When to Seek Help: Ultra-Levure

Official regulatory information for Ultra-Levure (Saccharomyces boulardii) addresses overdosage based on documented adverse effects observed at high intake levels and specific safety considerations for vulnerable patient populations.

Documented Overdose Presentations

In healthy individuals, the official overdose profile is characterized by generally minor and self-limiting gastrointestinal effects. The documented manifestations of overdosage include:

Gas (Flatulence)
Constipation

These minor symptoms are generally expected to resolve upon discontinuation of the product or reduction of the dose.

When Immediate Medical Help Is Required

Urgent medical attention should be sought if any symptoms resulting from an overdosage are persistent or if there is any concern about the exposure level. In case of an overdose, regulatory guidelines advise seeking medical help or contacting Poison Control.

Population-Specific Overdose Context

While direct toxicity in healthy adults is low, severe risks related to localized or systemic infection (fungemia) have been reported in highly vulnerable groups. Official safety context advises against the use of Saccharomyces boulardii in patients who are critically ill, severely immunocompromised, or have a central venous catheter. This risk profile forms a critical part of the overdose safety narrative for these specific populations, necessitating immediate medical evaluation if exposure or suspicion of infection occurs.

Therapeutic Uses of Ultra-Levure

What Ultra-Levure Treats: Main Uses and Benefits

Ultra-Levure (Saccharomyces boulardii) is commonly used to help with symptoms related to systemic imbalance in the gut, offering supportive therapeutic relief across several domains of gastrointestinal instability. It is utilized in areas where short-term symptom management is appropriate.

The agent is applied in contexts involving acute diarrheal episodes, including those associated with rotavirus in pediatric patients, and is commonly used to help with the prevention of Antibiotic-Associated Diarrhea (AAD) during courses of antibiotic therapy. Furthermore, it is relevant in settings marked by temporary physiological imbalance, such as the management of traveler's diarrhea and providing adjunctive support for symptoms in conditions like Irritable Bowel Syndrome (IBS).

This supportive role helps maintain a sense of stability when symptoms are more noticeable, contributing to easing the overall symptom load.

“It is relevant for easing symptoms associated with reducing the severity and duration of the episode, which may help patients cope more steadily with difficult episodes.”

Quick Fact: Supports Diarrheal Manifestations and Abdominal Discomfort

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Ultra-Levure (Saccharomyces boulardii) is strictly defined by regulatory warnings concerning the risk of systemic fungal infection (fungemia), particularly in vulnerable patients.

Contraindicated Populations

The medicine is absolutely contraindicated for patients who are immunocompromised, critically ill, or have a central venous catheter (CVC). Use is also prohibited if there is a known allergy to yeast or any component of the product.

Age and Physiological Restrictions

Ultra-Levure is typically permitted for adults and children over 6 years of age. Use in older adults should be with caution due to an increased risk of fungemia. The medicine is not recommended during pregnancy or breastfeeding due to insufficient reliable safety data. Caution is also advised for patients with certain hereditary sugar intolerances related to the product’s excipients.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The interaction profile of Ultra-Levure (Saccharomyces boulardii) is strictly governed by its status as a live, non-pathogenic yeast (fungus), leading to two primary domains of officially documented constraints: pharmacodynamic antagonism and population-specific prohibitions.

Interacting Medicinal Products and Substances:

Category	Officially Documented Interaction/Restriction
Antifungal Agents	Co-administration is a contraindicated combination. Systemic or oral antifungal medicinal products (e.g., fluconazole, ketoconazole, nystatin) are officially documented to decrease or negate the activity of the S. boulardii active ingredient.
Food / Liquids	The product must not be mixed with or ingested with very hot liquids or food (above 50 C), iced food/drinks, or alcohol-containing beverages/foods, as these factors physically inactivate the live yeast cells.

Population-Specific Prohibitions

Official regulatory documents from agencies such as the EMA mandate warnings and contraindications related to patient vulnerability. The product is prohibited or requires major caution in specific, clinically defined populations due to the officially documented risk of fungemia (fungal bloodstream infection):

Immunocompromised Patients
Critically Ill Patients
Patients with a Central Venous Catheter (CVC)

Procedural constraints in the regulatory labels also advise that capsules or sachets should not be opened in the immediate vicinity of CVC patients to prevent environmental contamination.

Mechanism of Action

Toxin Inactivation and Pathogen Shielding

The mechanistic activity begins within the gut lumen, where the yeast acts via enzymatic degradation and competitive exclusion. It secretes proteases that specifically inactivate key pathogenic bacterial toxins (e.g., C. difficile Toxin A/B) and utilizes its surface to inhibit pathogen adhesion to the intestinal lining. This action functionally limits the activity of harmful substances at the mucosal surface, resulting in reduced fluid movement into the intestinal lumen.

Barrier Stabilization and Fluid Homeostasis

The product engages host cellular pathways to support gut structural integrity. It modulates signal transduction by inhibiting the phosphorylation of MLC Kinase, a step crucial for maintaining the tight junction proteins (like ZO-1 and occludin) that seal the space between enterocytes. This mechanism supports the integrity of the intestinal barrier and actively counteracts secretagogue-induced signaling, which typically drives excessive secretion of water and ions, contributing to the maintenance of established fluid and electrolyte transport pathways.

Local Immune Modulation and Epithelial Repair

The yeast stimulates the production of trophic factors while modulating local inflammatory responses. It supports cellular function by stimulating the production of polyamines that enhance enterocyte growth and survival. Concurrently, it reduces pro-inflammatory signaling by inhibiting the activation of the NF-kappaB pathway in mucosal cells, which influences the local inflammatory environment and promotes the restoration of the epithelial surface.

Dosage and Administration Information

Official Administration Guidelines

Ultra-Levure (Saccharomyces boulardii) is administered solely via the oral route and is available as hard capsules or powder for oral suspension (sachets). The dosage and method of administration are established to ensure the active yeast component remains viable.

Standard Dosing and Schedule

Standard adult and adolescent dosing is generally in the range of 250 mg to 500 mg total daily dose of the lyophilized yeast. This regimen is often taken in one to two divided doses daily (BID). For example, some formulations recommend one 250 mg sachet or capsule taken twice daily. Treatment duration is typically short-term, with the need for continued use re-evaluated if symptoms persist beyond two days.

Preparation and Handling

The powder form should be mixed with water, juice, or milk, while capsules can be swallowed whole. It is a procedural requirement that the medicine must not be mixed with any liquid or food that is too hot (over 50°C), iced, or alcoholic, as these conditions can inactivate the live yeast cells.

For administration, the medicine can be taken with or without food, although some prescribing information advises taking it preferably before meals.

Age-Specific Rules and Restrictions

Specific age restrictions apply to the dosage form. The capsule form is contraindicated for children under 6 years of age due to the risk of aspiration. In applicable pediatric patients, the dose is frequently the same as the adult dose, using the powder form for younger children. Furthermore, Ultra-Levure must not be taken concurrently with systemic or oral antifungal medications due to the potential for drug inactivation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ultra-Levure

This section describes the types of scientific research that have been conducted regarding the use of Ultra-Levure (Saccharomyces boulardii), detailing what was studied and what still remains uncertain. This information is for context only and is not medical advice or a recommendation for use.

Evidence for use in Preventing Diarrhea Associated with Antibiotics (AAD)

Research has primarily focused on how Ultra-Levure use was monitored in studies exploring short-term outcomes related to antibiotic-associated diarrhea (AAD). This was studied for both adults and children who were prescribed antibiotics. Researchers used structured, short-term Randomized Controlled Trials (RCTs) and then pooled the data into systematic reviews. The main outcomes that were measured related to the incidence (how often it occurred) of AAD and how often patients developed other outcomes, such as Clostridioides difficile-associated diarrhea (CDAD).

Studies reported that the measured incidence of AAD varied between the group receiving the intervention and the control group during and immediately following antibiotic treatment. Long-term effects are not fully established, and evidence quality varies across studies due to differences in trial design details.

Evidence for use in Treating Acute Infectious Diarrhea

Ultra-Levure was studied for its use during periods of heightened symptoms associated with acute infectious diarrhea. Research explored short-term symptom changes by monitoring outcomes such as the mean duration of diarrhea (how long it lasted) and the frequency of bowel movements. Some trials reported measurements of the average duration of diarrhea that differed between the groups, though findings related to specific changes in stool frequency were mixed.

Research explored various dosages and durations of use for this product for acute diarrhea, yet certainty remains low for areas like optimal administration. Limited comparative evidence exists between Ultra-Levure and other similar products or standard medical treatments for this condition. Furthermore, the results apply only to the populations studied, and there is limited information available on outcomes related to hospitalization or long-term recovery.

What is Still Uncertain About Ultra-Levure Research

Key evidence gaps relate to the long-term outcomes and the durability of observed patterns after people stop using the product. Limited comparative evidence exists to assess how Ultra-Levure compares to every other type of probiotic or intervention. The consistency of findings is affected by heterogeneity (variability) across studies, meaning that differences in patient groups, regimens, and study designs lead to variability in reported outcomes. The research provides insight into short-term changes but does not determine whether an individual will respond similarly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ultra-Levure (FAQ)

Q: What is the difference between Ultra-Levure and other typical probiotics?

According to official information, Ultra-Levure is classified as a non-pathogenic yeast (a type of fungus), unlike many common probiotics which are bacteria. This specific classification is noted for providing inherent resistance to antibacterial medications, allowing the active ingredient to maintain viability and presence in the gut even when taken at the same time as antibiotics.

Q: What are the most commonly reported side effects of Ultra-Levure?

Official regulatory documents classify flatulence (gas) as a common adverse reaction associated with using this product. Other gastrointestinal effects, such as constipation, have also been reported in clinical use. The full safety section contains a complete overview of all documented adverse effects.

Q: Can people with yeast allergies use Ultra-Levure?

The use of the product is absolutely contraindicated if an individual has a known allergy to yeast or any of the product’s components, as stated in regulatory warnings. Official labeling contains a complete list of ingredients to be reviewed if known allergies exist.

Q: Is it necessary to take Ultra-Levure with food?

Regulatory documents state the medicine can be taken with or without food. However, some product prescribing information advises taking it preferably before meals. Patients should reference the specific instructions provided on the packaging for their formulation.

Q: Can I use Ultra-Levure while pregnant or breastfeeding?

The medicine is not recommended for use during either pregnancy or breastfeeding. This is due to the officially stated insufficient reliable safety data regarding its use in these specific populations.

Q: How long can I continue taking Ultra-Levure?

Treatment duration is typically classified as short-term in official documents. Official regulatory documents advise re-evaluation if symptoms persist beyond a few days, such as two days in some regimens.

Q: Why is Ultra-Levure sometimes referred to as Saccharomyces boulardii?

Saccharomyces boulardii is the official name of the active ingredient contained within the product. This specific, non-pathogenic yeast strain is the active component defined in official documents.

Q: How does Ultra-Levure impact the gut microbiome?

The general purpose of the product, as noted in official sources, is to provide support for the restoration of the intestinal microbiota. Studies indicate that the introduction of this yeast helps to re-establish the overall ecological balance in the gut following an acute disturbance.

Q: Does Ultra-Levure need to be refrigerated?

The product is generally stored at Controlled Room Temperature (typically around 20 C to 25 C) when the container is unopened. However, official instructions require the product to be stored in the refrigerator (e.g., 2 C to 8 C) after the container is first opened to ensure the viability of the active ingredient.

Q: Can Ultra-Levure cause bloating or gas?

Official regulatory labeling classifies flatulence (gas) as a common adverse reaction associated with the product’s use. While 'bloating' is not specifically classified, flatulence is a common adverse reaction.

Q: Are there any long-term effects of using Ultra-Levure regularly?

Official overviews of the research state that long-term effects are not fully established in published scientific literature. Evidence gaps specifically relate to the durability of observed health patterns after stopping use.

Q: What happens if I accidentally miss a day of taking Ultra-Levure?

Official guidance on dosing, which applies to many regulated medicines and supplements, generally advises against taking extra product or double-dosing to make up for a missed dose. The instruction is to continue with the next scheduled dose.

Q: Is the active culture in Ultra-Levure killed by stomach acid?

Authoritative information regarding the pharmacological properties of the active ingredient indicates that the specific yeast strain is known to survive the gastric acidity and bile in the digestive tract. This property allows the yeast to reach the lower gut where it is intended to act.

Q: Are there different strengths of Ultra-Levure available?

Yes. Regulatory documents confirm that Ultra-Levure is authorized in various countries in multiple strengths. These formulations may include 100 mg, 200 mg, and 250 mg doses, which can come in capsule or sachet form.

Q: Is Ultra-Levure safe for people with diabetes?

Caution is advised in official labeling for patients with certain hereditary sugar intolerances related to the product’s excipients (non-active ingredients). Patients who manage blood sugar should note the official caution regarding excipients.

Q: Can Ultra-Levure cause a fever or chills?

The serious adverse reaction of fungemia (a yeast bloodstream infection) is documented in official reports, occurring predominantly in specific at-risk populations. Official information notes that fungemia has most often resulted in pyrexia (fever) in reported cases.

Q: Are there any dietary restrictions while taking Ultra-Levure?

Regulatory documents impose clear restrictions regarding the physical handling of the product. Regulatory documents advise against mixing the medicine with liquids or food that are too hot (above 50 C), iced, or alcoholic, as these conditions may physically inactivate the live yeast cells.

Q: Are there any known interactions between Ultra-Levure and alcohol?

Regulatory documents explicitly advise against mixing the product with alcohol-containing beverages or foods. This restriction is based on the fact that alcohol may physically inactivate the live yeast cells.

Q: Is Ultra-Levure the same as brewer's yeast?

Ultra-Levure's active ingredient, Saccharomyces boulardii, is a non-pathogenic yeast that belongs to the broader Saccharomyces cerevisiae species group (which includes brewer's yeast). However, S. boulardii is a specific strain with distinct documented properties and is not interchangeable with all common brewer's yeast products.

Q: Is Ultra-Levure safe for patients recovering from surgery?

Official warnings strictly prohibit the use of the product in critically ill patients and patients who have a central venous catheter (CVC) due to a higher risk of fungemia. These specific contraindicated categories are important considerations in the context of surgery recovery.

Q: Has Ultra-Levure been studied in combination with oral rehydration solutions?

Research reviews and official guidelines for certain conditions, such as acute gastroenteritis, often evaluate the use of Saccharomyces boulardii in conjunction with rehydration therapy as part of a comprehensive approach.

How should Ultra-Levure be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict environmental controls for Ultra-Levure (Saccharomyces boulardii) to ensure the viability of the live yeast component.

Requirement Area	Official Instructions
Temperature	Store at Controlled Room Temperature (e.g., 20 C to 25 C / 68 F to 77 F). Do not freeze.
Environmental Protection	Must be protected from moisture and heat, and kept in a dry, cool place.
Stability After Opening	The product is required to be stored in the refrigerator (2 C to 8 C) after the container is first opened.
Packaging	The container must be kept tightly closed.
Child Safety	Must be kept out of the reach of children.
Disposal	Unused or expired product must be properly discarded. Do not flush the medicine down the toilet or pour it into a drain unless instructed to do so by a pharmacist or waste disposal company.

Ultra-Levure